Patients who received further therapy
| Patient . | Time to next therapy, m . | Reason for next therapy . | Next therapy . |
|---|---|---|---|
| 36 | A) 1.6 | Worsening PN | A) Doxorubicin, corticosteroids |
| B) 4.1 | B) ASCT | ||
| 37 | 2.2 | Worsening PN | Bevacizumab, thalidomide |
| 18* | A) 3.3 | A) Worsening PN but improved skin findings and extravasation | A) CTX, corticosteroids |
| B) 32 | B) New bone lesion | B) Irradiation | |
| 13* | 3.5 | Worsening PN, lower extremity edema, endocrinopathy | ASCT |
| 25 | 4.6 | Worsening PN | ASCT |
| 32 | 6.0 | Worsening PN | ASCT |
| 9† | 6.5 | Return of fatigue and edema, worsening PN despite initial improvement (PN, skin, volume overload, and PET/CT) | ASCT |
| 5 | 6.9 | Inadequate PN improvement and worsening VEGF | ASCT |
| 20 | 7.6 | Inadequate PN improvement with worsening skin findings, volume overload, and papilledema | ASCT |
| 22 | 10.0 | Worsening PN and persistent M-spike | ASCT |
| 19 | 12.6 | Inadequate PN improvement | Lenalidomide, corticosteroids |
| 35† | A) 19 | A) New papilledema | A) Corticosteroids |
| B) 71 | B) New calvarial lesion | B) Irradiation | |
| 26*,† | 26.3 | Worsening VEGF and new bone lesions | ASCT |
| 12* | A) 28 | A) New bone lesions and adenopathy | A) Corticosteroids |
| B) 35 | B) Worsening PN | B) CTX, corticosteroids | |
| C) 43 | C) Worsening PN | C) CTX, corticosteroids | |
| 34† | 53 | Worsening VEGF, new bone lesions (20 m), new bone marrow involvement (27 m), and worsening skin (49 m) | ASCT |
| 27† | 66 | Worsening erythrocytosis and bone lesions by PET/CT | Lenalidomide, corticosteroids |
| 28† | 73 | Reemergence of M-spike and new bone lesion | Irradiation and CyberKnife concurrently |
| Patient . | Time to next therapy, m . | Reason for next therapy . | Next therapy . |
|---|---|---|---|
| 36 | A) 1.6 | Worsening PN | A) Doxorubicin, corticosteroids |
| B) 4.1 | B) ASCT | ||
| 37 | 2.2 | Worsening PN | Bevacizumab, thalidomide |
| 18* | A) 3.3 | A) Worsening PN but improved skin findings and extravasation | A) CTX, corticosteroids |
| B) 32 | B) New bone lesion | B) Irradiation | |
| 13* | 3.5 | Worsening PN, lower extremity edema, endocrinopathy | ASCT |
| 25 | 4.6 | Worsening PN | ASCT |
| 32 | 6.0 | Worsening PN | ASCT |
| 9† | 6.5 | Return of fatigue and edema, worsening PN despite initial improvement (PN, skin, volume overload, and PET/CT) | ASCT |
| 5 | 6.9 | Inadequate PN improvement and worsening VEGF | ASCT |
| 20 | 7.6 | Inadequate PN improvement with worsening skin findings, volume overload, and papilledema | ASCT |
| 22 | 10.0 | Worsening PN and persistent M-spike | ASCT |
| 19 | 12.6 | Inadequate PN improvement | Lenalidomide, corticosteroids |
| 35† | A) 19 | A) New papilledema | A) Corticosteroids |
| B) 71 | B) New calvarial lesion | B) Irradiation | |
| 26*,† | 26.3 | Worsening VEGF and new bone lesions | ASCT |
| 12* | A) 28 | A) New bone lesions and adenopathy | A) Corticosteroids |
| B) 35 | B) Worsening PN | B) CTX, corticosteroids | |
| C) 43 | C) Worsening PN | C) CTX, corticosteroids | |
| 34† | 53 | Worsening VEGF, new bone lesions (20 m), new bone marrow involvement (27 m), and worsening skin (49 m) | ASCT |
| 27† | 66 | Worsening erythrocytosis and bone lesions by PET/CT | Lenalidomide, corticosteroids |
| 28† | 73 | Reemergence of M-spike and new bone lesion | Irradiation and CyberKnife concurrently |